Jrdelane. I was about to post my take on technicals. The daily chart is showing the MACDwith a touch of positive divergence as the RSI is in oversold territory. NIce little reverse hammer showed as well. albeit on the late surge. Stoch look curled up and ready to turn. I believe we see 6 plus by next week.
interesting observation, yet my only challenge to this idea is that the funds that bought the secondary had already owned shares near the offering price thus they would be hurting themselves. You can argue that they will run it back up to make up losses on previous positions prior to secondary. Yet, I've been in the game awhile and I just don't think this is the case. my simple conclusion is that its new driven play and that everyone is positioned. gun powder has been utilized. thus , it trading down with no buy side interest until the new flock of momo traders come in with new news. MY humble opinion.
Per the tape and volume on Friday and Monday it seems new buyers stepped in versus just short covering. I believe the low volume today supports this thesis. I personally initiated a position on Friday. As, I assume others did. I now await news about the limited controlled roll-out to substantiate merit of tests from physician groups and patients. Regarding the noise on insiders needing to buy more. This team has been compensated with shares and options as part of there compensation package. As, all bio start up teams off set the more modest salaries and risk by upside in ownership. So, why would they go spend their cash to by more shares ? they don´t need too. Regarding the roll-out it seems like it methodical and strategic to ultimately capture a big foot print in this 15bb market. I´m personally going to remain patient and excited to be involved with these guys. Per all my Due Diligence , I believe TROV could have a 2 handle on it in the 12 months. All the above is my very humble opinion. Blessings.
Sentiment: Strong Buy
WILL MGMT USE A POISON PILL ? they are not only have US shares tendered but will buy shares on common market thus shares could move up quickly ? bottom line offer is to low. any coments
Does anyone have any clarity on this issue. I believe the FDA's blood sub committee agreed 16 to 1 that it was prudent to pass new requirements yet the FDA governing body rejected the committee's recommendation. Please advise. blessings. RG
restructuring eminent . new owners will restructure dept as they will not be able to walk away from it as there are asset liens on intellectual property or future cash flows. writ of attachment. nevertheless, this is toxic now. liquidate and move to sidelines. my HUMBLE 2 CENTS